




The relative strengths and weaknesses of Moonlake Immunotherapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moonlake Immunotherapeutics compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 225% points. The greatest weakness of Moonlake Immunotherapeutics is the variable Other Revenues, reducing the Economic Capital Ratio by 8.9% points.

The company's Economic Capital Ratio, given in the ranking table, is 439%, being 226% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	514,167
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,966
Liabilities, Non-Current	3,083
Other Assets	12,052
Other Compr. Net Income	9,567
Other Expenses	94
Other Liabilities	0
Other Net Income	0
Other Revenues	10,138
Property and Equipment	321
Research and Development	31,802
Selling, General and Administrative Expense	22,321

Output Variable	Value in 1000 USD
Assets	526,540
Liabilities	13,049
Expenses	54,217
Revenues	10,138
Stockholders Equity	513,491
Net Income	-44,079
Comprehensive Net Income	-39,295
BaseVar	306,756
ECR before LimitedLiability	400%
Economic Capital Ratio	439%